TMCnet News
Research and Markets: Global Prostate Cancer Therapeutics Market to 2019: Zytiga and Xtandi, has provided late-stage patients with a number of optionsDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/vhvpd8/prostate_cancer) has announced the addition of the "Global Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019" report to their offering. Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%. Scope
Key Topics Covered: 1. Tables & Figures 2 Introduction 3 Marketed Products 4 Prostate Cancer Developmental Pipeline 5 Market Forecast to 2019 6 Prostate Cancer Therapeutics: Drivers and Barriers 7 Licensing and Co-development Deals Analysis 8 Appendix Companies Mentioned - AstraZeneca - Abbvie - Ferring - Sanofi - Dendreon - Janssen - Astellas/Medivation - Bayer/Algeta - Amgen - Novartis For more information visit http://www.researchandmarkets.com/research/vhvpd8/prostate_cancer
|